The pharma giant Marinus has made headlines in recent weeks with its blockbuster announcement of the creation of a new line of generic medicines, and its stock price has seen it rise almost 70 per cent in the past few months.
In March, the company announced it had completed the development of a brand-new line of drugs that will be available as a generic form, which could pave the way for its own generic medicines to be available.
The company’s stock has since increased over 80 per cent over the past five years.
A lot of people have been expecting Marinus to go public, but the company’s management has been keeping mum on the possibility of going public, and has remained mum on a stock price increase.
The company is set to unveil its new generic drugs at the end of the year, and if the company continues to see a rise in its share price, investors will be keen to see what the new generics will be like.
It’s not just about making a brand new brand of generic drugs, but about the generics themselves.
Marinus is aiming to take the new drugs in a range of different classes and have them available as generics.
“It’s all about building a range, building a brand, building new products and creating brand awareness,” Marinus CEO Mark Smith said in an interview.
“You can build a brand around new drugs and new drugs will become brand names.”
What I would hope is that people recognise it, people are aware of it and we will be able to help to build awareness around it.
“Marinus is also looking to expand its generic drugs in other markets, with the announcement of a joint venture with Pfizer to develop an anti-cancer drug called Misdiagnosis.
The new generic drug, which will be known as Misdio, will also be a brand name, but Smith says it will be a different drug from the generic that has already been developed.”
We’re not going to be going down a very generic path,” he said.”
Our Misdius is going to have brand recognition.
“When it comes to our generic drug which will have brand identification, we’re not looking at any generic in that particular drug class.”
So we’re going to look at a new drug that will have a very different clinical profile from the Misdios that we have now.
“That will be the Misfio, the brand name will be Misdias, and the generic will be an off-the-shelf drug.”
While the new generic will only be available for people in Australia and New Zealand, it could be available to patients around the world.
Smith said Marinus would work closely with its overseas manufacturing partners, to ensure the new drug was as safe and effective as the generic currently on the market.
“The manufacturing partners will be responsible for ensuring that the Mislios we are going to supply are as safe, effective and well-tested as those on the global market,” Smith said.